Eltrombopag is approved for the treatment of chronic immune thrombocytopenia purpura (ITP) in pediatric patients 1 year and older who have demonstrated an insufficient response to corticosteroids and intravenous immunoglobulin. We present the case of a 2-year-old boy with chronic immune thrombocytopenia purpura who developed life-threatening adverse effects of acute liver failure, metabolic acidosis and encephalopathy with standard drug dosing. To our knowledge, this is the first case of eltrombopag-induced hepatic encephalopathy highlighting the critical need for prescribers to exercise caution when prescribing eltrombopag in the pediatric setting.

中文翻译：

---

艾曲波帕诱导的小儿 ITP 代谢性酸中毒和肝性脑病。

艾曲波帕被批准用于治疗对皮质类固醇和静脉注射免疫球蛋白反应不足的 1 岁及以上儿童患者的慢性免疫性血小板减少性紫癜 (ITP)。我们介绍了一名患有慢性免疫性血小板减少性紫癜的 2 岁男孩的病例，他在标准药物剂量下出现了急性肝衰竭、代谢性酸中毒和脑病等危及生命的不良反应。据我们所知，这是首例艾曲波帕诱导的肝性脑病病例，强调了在儿科环境中开具艾曲波帕时，处方医生必须谨慎行事。